Zynerba Pharmaceuticals — Investor Presentation (October 2017)
34 slides from Zynerba Pharmaceuticals's investor presentation, Oct 11, 2017
Slide 1: Disclaimer
Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,
Slide 2: Company Highlights
Company Highlights 3 Dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid therapeutics Experienced team with proven track record in CNS and pain, and patch / gel transdermal deliveries, such as Testim® and Zecuity® Two potentially pivotal study-rea
Slide 3: Compelling Pipeline with Multiple Near-Term Milestones
Compelling Pipeline with Multiple Near-Term Milestones 4 ZYN002 patent protected through 2030 ZYN001 patent protected through 2031 Product Candidate Indication Preclinical Phase 1 Phase 2 Next Milestones ZYN001 – THC Pro-Drug Patch ZYN002 – CBD Gel Epilepsy in Adults with Focal Seizures Osteoarthrit
Slide 4: ZYN002 CBD Gel Clinical Program
5 ZYN002 CBD Gel Clinical Program Developing pharmaceutically-produced CBD formulated as a patent-protected permeation-enhanced gel
Slide 5: ZYN002 – CBD Gel
ZYN002 – CBD Gel First and only patent-protected permeation-enhanced pharmaceutically-produced cannabidiol gel formulated for transdermal delivery The permeation enhancer in ZYN002 increases the delivery of CBD through the layers of the epidermis and into the circulatory system 6 CBD Delivery
Slide 6: ZYN002 CBD Gel Clinical Program: Fragile X Syndrome
7 ZYN002 CBD Gel Clinical Program Fragile X Syndrome
Slide 7: Fragile X Syndrome (FXS) Overview
Fragile X Syndrome (FXS) Overview 8 Autism spectrum disorder with no approved treatment options ~71,000 US patients1; most common inherited intellectual disability X-linked dominant; affects both males and females2 Intellectual disability, attention problems, anxiety, social avoidance co-occur Autis
Slide 8: Fragile X Syndrome Caused by FMR1 Mutation
Fragile X Syndrome Caused by FMR1 Mutation 9 Caused by a mutation in the Fragile X Mental Retardation gene located on the X chromosome Leads to dysregulation of the endocannabinoid pathway including the reduction in endogenous cannabinoids (2-AG and anandamide) Negatively affects synaptic function,
Slide 9: CBD’s Potential in Fragile X Syndrome
CBD’s Potential in Fragile X Syndrome Strong scientific rationale for CBD in FXS In mouse knock-out model, inhibition of metabolism of 2-AG improves symptoms CBD inhibits metabolism of anandamide and 2-AG, increasing their availability Strong anxiolytic properties due to serotonin receptor 5-HT1A ac
Slide 10: Fragile X Syndrome Phase 2 Clinical Trial
Fragile X Syndrome Phase 2 Clinical Trial 11 Maintenance Dosing initiated at CBD 50 mg Daily; may be titrated up to 250 mg* Daily Screening Titration Weeks 7 to 12 Day 1 to Week 6 Open label, doses of CBD 50 mg, 100 mg, or 250 mg* Daily 18 patients completed study *In 4.2% gel 20 patients enrolled T
Slide 11: FAB-C Endpoints
FAB-C Endpoints 12 Changes in Anxiety, Depression and Mood vs. Baseline as Measured by the ADAMS Scale Primary Endpoint (recommended by FDA) Secondary Endpoints Aberrant Behavior Checklist – FXS Specific (ABC-FXS) Clinical Global Impression – Improvement (CGI-I) Pediatric Anxiety Rating Scale (PARS-
Slide 12: Positive ZYN002 FAB-C Phase 2 Efficacy Data: ADAMS
Positive ZYN002 FAB-C Phase 2 Efficacy Data Primary Endpoint: ADAMS Total Score ADAMS total score Improvement vs. baseline (N=20) Changes in Anxiety, Depression and Mood 46% (p<0.0001) ADAMS subscales Improvement vs. baseline (N=20) General Anxiety 54% (p<0.0001) Social Avoidance 53% (p<0.0002) Comp
Slide 13: ADAMS Subscales Week 12: Percent Improvement vs. 3rd party data
ADAMS Subscales Week 12: Percent Improvement vs. 3rd party data* 14 Manic/hyperactive Behavior Depressed Mood Social Avoidance General Anxiety Compulsive Behavior Baseline: 9.4 Baseline: 8.1 8.7 Baseline: 2.8 Baseline: 3.0 3.1 Baseline: 10.2 Baseline: 6.9 7.5 Baseline: 10.0 Baseline: 7.9 8.3 Baselin
Slide 14: Positive ZYN002 FAB-C Phase 2 Efficacy Data: ABC-FXS
Positive ZYN002 FAB-C Phase 2 Efficacy Data Key Secondary Endpoint: ABC-FXS 15 ABC-FXS subscale Improvement vs. baseline (N=20) Stereotypy: "Repetitive Movements" 59% (p=0.0006) Social Avoidance: "Seeks Isolation" 55% (p=0.0005) Socially Unresponsive/Lethargic: "Does Not Pay Attention" 53% (p=0.0034
Slide 15: ABC-FXS Subscales Week 12: Percent Improvement vs. 3rd party data
ABC-FXS Subscales Week 12: Percent Improvement vs. 3rd party data* 16 Irritability Temper Tantrums Hyperactivity Disrupts Group Activities Socially Unresponsive / Lethargic Does Not Pay attention Social Avoidance Seeks Isolation Stereotypy Repetitive Movements Baseline: 18.2 Baseline: 18.9 19.6 Base
Slide 16: Positive ZYN002 FAB-C Phase 2 Safety Data
17 Very well tolerated, consistent with previously reported clinical data Two sibling patients discontinued due to worsening of pre-existing eczema Four other patients experienced an AE; no SAEs No drug-related GI events No THC was detected in the plasma 13 patients continued into open label extensi
Slide 17: ZYN002 in Fragile X Syndrome: Next Steps
18 ZYN002 in Fragile X Syndrome: Next Steps Expect to meet with FDA in 1H18 to discuss data and pivotal trial design Goal to move quickly into pivotal Phase 2/3 program in pediatric and adolescent patients with FXS in 2018 Assessing opportunity to present / publish full data set as soon as possible
Slide 18: ZYN002 CBD Gel Clinical Program: Osteoarthritis
19 ZYN002 CBD Gel Clinical Program Osteoarthritis
Slide 19: Potential Path Forward for ZYN002 in Osteoarthritis
Potential Path Forward for ZYN002 in Osteoarthritis 20 Phase 2 study data help clarify efficacy, safety, dose, inclusion and exclusion criteria, primary and secondary endpoints, placebo response in OA patients FDA guidelines require pain and function endpoints in pivotal OA programs ZYN002 achieved
Slide 20: ZYN002 CBD Gel Clinical Program: Focal Seizures in Epilepsy
21 ZYN002 CBD Gel Clinical Program Focal Seizures in Epilepsy
Slide 21: STAR Study of ZYN002 in Focal Seizures
STAR 1 Study of ZYN002 in Focal Seizures 22 Primary and secondary endpoints did not reach statistical significance compared to placebo Excellent tolerability, consistent with previously reported data Clinically meaningful reductions (>30%) of seizures seen in ongoing STAR 2 open label extension Pati
Slide 22: ZYN001 THC Pro-Drug Patch Clinical Program
23 ZYN001 THC Pro-Drug Patch Clinical Program Studying a pharmaceutically-produced pro-drug of THC in a state-of-the-art drug-adhesive matrix transdermal patch
Slide 23: ZYN001 – THC Pro-Drug Patch
ZYN001 – THC Pro-Drug Patch 24 Patent-protected pharmaceutically-produced D-glyceric acid ester-Δ9-tetrahydrocannabinol in a transdermal patch ZYN001 is a pro-drug A drug administered in an inactive or less active form, designed to enable more effective delivery, and then converted into a different
Slide 24: Potential Benefits of Patch Technology
Note: Based upon FDA approved patch products. These results are not indicative of any preclinical or clinical data for ZYN001. Potential Benefits of Patch Technology 25 Requirement Purpose Non-oral Avoids first-pass metabolism with increased bioavailability and more consistent plasma levels Controll
Slide 25: Potential for THC in Large Indications
Has an analgesic effect in chronic pain models Acts at many sites along pain transmission pathways Third-party clinical data on Nabilone (THC analogue) in patients with fibromyalgia supportive of rationale Approximately 6 million US patients* Potential for THC in Large Indications Role as a CB1 Agon
Slide 26: ZYN001 Phase 1 Clinical Trial Underway
ZYN001 Phase 1 Clinical Trial Underway 27 24 hours 3.5 days 7 days Part 2: Multiple Dose Part 1: Single Dose 3:1 randomization, placebo controlled Multiple doses over 14 days Two formulations selected from Part 1 Multiple formulations of ZYN001 tested in each group 3:1 randomization, placebo control
Slide 27: ZYN001 Phase 1 Clinical Program Ongoing
ZYN001 – THC Pro-Drug Patch Phase 1 Clinical Program Ongoing 28 Trial Patients Dosing PD Evaluations Phase 1 program: Part 1: Single Rising Doses in Normal Subjects Pharmacokinetic profile and tolerability evaluation of multiple formulations of ZYN001 Part 2: Multiple Rising Doses in Normal Subjects
Slide 28: ZYN001 Preliminary Phase 2 Clinical Plan
29 Note: Subject to change due to further regulatory, clinical and other considerations. Trial Patients Dosing Primary Endpoint Timing Efficacy and Tolerability in Patients with Fibromyalgia Double-blind, placebo-controlled 120 patients 12 weeks Change from baseline in Fibromyalgia Impact Questionna
Slide 29: Strong Balance Sheet Provides Expected Runway into 2019
30 $70.2 million in cash & cash equivalents* We believe that cash is sufficient to fund operations and capital requirements into 2019, including: Completing development of STAR 1 & 2, STOP and FAB-C Phase 2 trials for ZYN002 Completing Phase 1 and Phase 2 studies for ZYN001 Assuming support from FDA
Slide 30: Zynerba Remains Well Positioned in the High-Growth Cannabinoid Space
Zynerba Remains Well Positioned in the High-Growth Cannabinoid Space 31 Zynerba’s transdermal approach has significant benefits Patent protection Scalable pharmaceutical manufacturing process Attractive COGS and no royalty obligations Sustained, controlled blood levels of drug with excellent tolerab
Slide 31: Scientific Advisors
Randi J. Hagerman, MD Medical Director, UC Davis MIND Institute, Distinguished Professor, Endowed Chair in Fragile X Research, Department of Pediatrics, UC Davis School of Medicine Steven J. Siegel, MD, PhD Chair, Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University
Slide 32: Investor Relations
Investor Relations 33 NASDAQ: ZYNE Analyst Coverage* Jefferies: Biren Amin, PhD Piper Jaffray: Charles C. Duncan, PhD Oppenheimer: Derek Archila H.C. Wainwright: Oren Livnat Roth: Michael Higgins Canaccord Genuity: Arlinda Lee, PhD Cantor Fitzgerald: Elemer Piros, PhD Maxim: Gabrielle Zhou * Note: A
Slide 33: Zynerba Pharmaceuticals – October 2017
October 2017 A clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for patients with high unmet medical needs
Slide 34: Aclini ialty pharmaceutical
Aclini ialty pharmaceutical company dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for patients with high unmet medical n October 2017
Zynerba Pharmaceuticals — Investor Presentation (October 2017) on 6ix